Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 20/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 20/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 20/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101975 | 1.00 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL13999214 | 1.00 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL13999215 | 0.91 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL13999213 | 0.91 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL5101829 | 0.83 | ADRA1A (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL5112041 | 0.83 | ADRA1A (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL5101822 | 0.83 | ADRA1A (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13999208 | 0.81 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL5110677 | 0.81 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL5101641 | 0.78 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470711-B2 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | claimed |
| US-20060217419-A1 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-28 | — | — | US | claimed |
| US-7470711-B2 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | disclosed |
| US-20060217419-A1 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217419-A1 | Piperidinyl substituted cyclohexane-1,4-diamines | ADRA1D, ADRA1A, ADRB1 | DRD2 98/4885ADRA1D 1/4885ADRA1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.